TABLE 2. Effectiveness of updated 2023–2024 (monovalent XBB.1.5) COVID-19 vaccination against laboratory-confirmed COVID-19–associated hospitalization among immunocompromised adults aged ≥18 years — VISION, September 2023–February 2024.
| COVID-19 vaccination dosage pattern | Total | Positive SARS-CoV-2 test result, no. (%) | Median interval since last dose, days (IQR) | Unadjusted VE, %* (95% CI) | Adjusted VE, %† (95% CI) |
|---|---|---|---|---|---|
| No updated dose§ (Ref) |
11,990
|
1,197 (10) |
587 (381–766) |
Ref
|
Ref
|
| Received updated dose |
2,596
|
195 (8) |
56 (32–81) |
27 (14–37)
|
36 (25–46)
|
| 7–59 days earlier |
1,381
|
100 (7) |
34 (21–46) |
30 (13–43)
|
38 (23–50)
|
| 60–119 days earlier | 1,215 | 95 (8) | 83 (71–98) | 24 (5–38) | 34 (16–47) |
Abbreviations: Ref = referent group; VE = vaccine effectiveness; VISION = Virtual SARS-CoV-2, Influenza, and Other respiratory viruses Network.
* VE was calculated as (1 – odds ratio) × 100%, with odds ratios calculated using logistic regression.
† The odds ratio was adjusted for age, sex, race and ethnicity, geographic region, and calendar time (days since January 1, 2021).
§ The “no updated dose” group included all eligible persons who did not receive an updated COVID-19 vaccine dose, regardless of number of previous (i.e., original monovalent and bivalent) doses (if any) received.